Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline

被引:49
|
作者
Spina, E
Avenoso, A
Salemi, M
Facciolá, G
Scordo, MG
Ancione, M
Madia, A
机构
[1] Univ Messina, Policlin, Inst Pharmacol, I-98125 Messina, Italy
[2] Azienda USL 5, Ctr Mental Hlth, Messina, Italy
关键词
D O I
10.1055/s-2000-8361
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p < 0.01) and by 20% (p < 0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/ clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline. Clozapine coadministration with either paroxetine or sertraline was well tolerated. Our findings suggest that the metabolism of clozapine is not affected by sertraline treatment at typical therapeutic doses, while paroxetine, a potent inhibitor of CYP2D6, appears to inhibit the metabolism of clozapine, possibly by affecting pathways other than N-demethylation and N-oxidation. While sertraline may be added safely to patients on maintenance treatment with clozapine, careful clinical observation and monitoring of plasma clozapine levels may be useful whenever paroxetine is coadministered with clozapine.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [21] PLASMA AND SYNOVIAL-FLUID CONCENTRATIONS OF DICLOFENAC SODIUM AND ITS MAJOR HYDROXYLATED METABOLITES DURING LONG-TERM TREATMENT OF RHEUMATOID-ARTHRITIS
    FOWLER, PD
    SHADFORTH, MF
    CROOK, PR
    JOHN, VA
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 25 (03) : 389 - 394
  • [22] Therapeutic Reference Range for Plasma Concentrations of Paroxetine in Patients With Major Depressive Disorders
    Tomita, Tetsu
    Yasui-Furukori, Norio
    Nakagami, Taku
    Tsuchimine, Shoko
    Ishioka, Masamichi
    Kaneda, Ayako
    Nakamura, Kazuhiko
    Kaneko, Sunao
    THERAPEUTIC DRUG MONITORING, 2014, 36 (04) : 480 - 485
  • [23] Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine
    Kennedy, SH
    Eisfeld, BS
    Dickens, SE
    Bacchiochi, JR
    Bagby, RM
    JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (04) : 276 - 281
  • [24] Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment
    Fava, M
    Judge, R
    Hoog, SL
    Nilsson, ME
    Koke, SC
    JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) : 863 - 867
  • [25] Relation of blood counts during clozapine treatment to serum concentrations of clozapine and nor-clozapine
    Oyewumi, LK
    Cernovsky, ZZ
    Freeman, DJ
    Streiner, DL
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (03): : 257 - 261
  • [26] PLASMA-CONCENTRATIONS OF CHLORPROMAZINE AND MAJOR METABOLITES IN HUMAN VOLUNTEERS
    YEUNG, PKF
    WALLACE, SM
    HUBBARD, JW
    MIDHA, KK
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1986, 9 (04): : C6 - C6
  • [27] Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients
    Jann, MW
    Liu, HC
    Wei, FC
    Lin, SK
    Lin, SK
    Hu, WH
    Chang, WH
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1997, 12 (05) : 489 - 495
  • [28] Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients
    Liu, HC
    Chang, WH
    Wei, FC
    Lin, SK
    Lin, SK
    Jann, MW
    THERAPEUTIC DRUG MONITORING, 1996, 18 (02) : 200 - 207
  • [29] Psychomotor Changes in Major Depressive Disorder during Sertraline Treatment
    Schrijvers, D.
    Maas, Y. J.
    Pier, M. P. B. I.
    Madani, Y.
    Hulstijn, W.
    Sabbe, B. G. C.
    NEUROPSYCHOBIOLOGY, 2009, 59 (01) : 34 - 42
  • [30] Transport of clozapine and its major metabolites into human cells of glial and neuronal origin
    Henning, U
    Krieger, K
    Loeffler, S
    Klimke, A
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 233 - 233